Financial insights of PFE

MyFinsight

For the quarter ending 2025-09-28, PFE made $16,438M in revenue. $3,541M in net income. Net profit margin of 21.54%.

Unit: Million (M) dollars (except for numbers of shares and EPS)

Income Statement	2025-09-28	2025-06-29	2025-03-30	2024-09-29
Less net income attributable to noncontrolling interests	9	18	6	8
Provision/(benefit) for taxes on income	-216	141	-189	234
Cost of sales	4,172	3,778	2,845	5,263
Selling, informational and administrative expenses	3,186	3,415	3,031	3,244
Research and development expenses	2,546	2,482	2,203	2,598
Acquired in-process research and development expenses	1,390	2	9	13
Amortization of intangible assets	1,223	1,211	1,211	1,312
Restructuring charges and certain acquisition-related costs	286	-18	678	313
Other (income)/deductionsnet	-517	-739	-953	-243
Total revenues	16,654	14,653	13,715	17,702
Income from continuing operations before provision/(benefit) for taxes on income	3,334	3,044	2,785	4,715
Income from continuing operations	3,550	2,903	2,973	4,481
Discontinued operationsnet of tax	0	25	0	-8
Net income before allocation to noncontrolling interests	3,550	2,928	2,973	4,473
Net income attributable to pfizer inc. common shareholders	3,541	2,910	2,967	4,465

Net income attributable to pfizer inc. common shareholders (in dollars per share)	0.62	0.51	0.52	0.79
Net income attributable to pfizer inc. common shareholders (in dollars per share)	0.62	0.51	0.52	0.78
Weighted-average shares--basic (in shares)	5,685,000,000	5,685,000,000	5,675,000,000	5,667,000,000
Weighted-average shares--diluted (in shares)	5,714,000,000	5,706,000,000	5,710,000,000	5,705,000,000